Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin
Feb 28, 2026, 16:49

Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin

Céline Chapelle, Biostatistician at Saint-Étienne University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:

“New Research Alert!

I am excited to share our latest co-authored study, now published in Blood Advances, focusing on the management of Cancer-Associated Thrombosis (CAT).

Using pooled data from 1,413 patients, we evaluated the 6-month risks of recurrent VTE and major bleeding (MB) in patients treated with tinzaparin.

Our findings reveal a critical nuance in how we view patient risk:

  • Tumor Site Matters: Recurrent VTE risk surpassed bleeding risk in lung and GI cancers, while the opposite was true for breast cancer.
  • The ‘Frailty’ Factor: In frail patients (age greater than or equal to 75, low body weight, or renal impairment), the risk of VTE recurrence increases with the number of frailty factors—yet, surprisingly, the risk of major bleeding remains relatively stable.
  • Clinical Takeaway: In frail patients with CAT, the risk of VTE recurrence outweighs the risk of bleeding. Our findings suggest that standard full-dose tinzaparin should be maintained in this population.

This study underscores that in CAT, one size does not fit all. Understanding the specific interplay between tumor site and patient frailty is key to optimizing anticoagulation.

A huge thank you to my co-authors and the teams across the four prospective studies for this massive collaborative effort!”

Title: Complications in Cancer Associated Thrombosis patients on tinzaparin by cancer site and frailty: a pooled analysis

Authors: Isabelle Mahe, Celine Chapelle, Philippe Girard, Luis Jara-Palomares, Agnes YY Lee, Olivier Sanchez, Guy Meyer, Patrick Mismetti, Silvy Laporte

Read the Full Article on Blood Advances

Céline Chapelle: Evaluating 6-Month Risks of Recurrent VTE and Major Bleeding With Tinzaparin

Stay updated with Hemostasis Today.

Agnes YY Lee bleeding disorders Blood Advances Cancer Associated Thrombosis Celine Chapelle Guy Meyer Health Hematology Hemostasis News Hemostasis Today Isabelle Mahé Luis Jara-Palomares major bleeding Medicine Olivier Sanchez Patrick Mismetti Philippe Girard Silvy Laporte Tinzaparin VTE
NewsFeed